Business
Gilead refreshes ADC biomarker collab with Nucleai
Israel-based Nucleai announced an ongoing translational research collaboration with Gilead Sciences supporting Gilead's global antibody-drug conjugate (ADC)...
AbCellera offers up USD 200m in stock to support NK3 menopause antibody
Canada-based AbCellera Biologics Inc. (Nasdaq: ABCL) announced a proposed underwritten public offering of common stock and pre-funded warrants targeting USD...
Vogenx prices USD 81.3m IPO to fund SGLT1-targeted mizagliflozin
Raleigh, North Carolina-based Vogenx, Inc. (Nasdaq: VOGX), a clinical-stage biopharmaceutical company developing treatments for metabolic conditions with no...
Sentynl gains US rights to Mereo's Phase III alvelestat for alpha-1 lung disease
Mereo BioPharma (Nasdaq: MREO) and Solana Beach, California-based Sentynl Therapeutics have entered an option and license agreement granting Sentynl...
Menarini bets EUR 726m on Gan & Lee’s biweekly GLP-1
Gan & Lee Pharmaceuticals (SSE: 603087) has signed an exclusive licensing agreement with Italy-based The Menarini Group granting the European pharmaceutical...
AB Science raises EUR 14.2m to fund masitinib Phase III, AB8939
France-based AB Science S.A. (Euronext Paris: AB) announced the completion of a EUR 14.2 million (approximately USD 15.5 million) private placement on...
Infinimmune raises USD 75m to bring IL-22 antibody into clinic
Alameda, California-based Infinimmune, a biotechnology company developing antibody therapeutics derived directly from the human immune system, has closed a...
Epicrispr raises USD 90m to advance first-in-class epigenetic therapy into pivotal FSHD studies
South San Francisco-based Epicrispr Biotechnologies has closed a USD 90 million oversubscribed Series C financing round to advance its lead epigenetic gene...
Oculis rebuilds pipeline with Privosegtor buy from Accure
Switzerland-based Oculis Holding AG (Nasdaq: OCS) has agreed to acquire all worldwide development and commercial rights to Privosegtor from Spain-based...
Avere raises USD 500m for once-weekly IL-23R challenger to Icotyde
San Francisco-based Avere Therapeutics announced a USD 500 million private placement on August 10, 2026, to fund clinical development of AVR-001 (HS-20118),...
China's Hopstem secures Series backing for iPSC neural cell therapy pipeline
China-based Hopstem Biotechnology Inc. has closed the first tranche of a Series C financing round to advance its induced pluripotent stem cell...
Curium continues to expand oncology PET pipeline with Abscint acquisition
Curium has completed the acquisition of Abscint SA, a Belgium-based clinical-stage radiopharmaceutical company, adding ABS-011, an investigational...
Remedium Bio's obesity gene therapy platform picks up Lilly support in USD 10m Series A
Boston-based Remedium Bio, Inc. has closed a USD 10 million Series A financing round to advance its Prometheus gene therapy platform toward first-in-human...
Aureka closes USD 100m Series B to scale biological AI foundation models for drug discovery
Laguna Hills, California-based Aureka Biotechnologies has closed a USD 100 million Series B financing round to advance its AI-native drug discovery platform...
Vaderis raises USD 152m to advance engasertib into Phase III HHT trial
Switzerland-based Vaderis Therapeutics AG has closed an oversubscribed USD 152 million Series B financing by private placement, simultaneously announcing...
The AllSci Brief
Free, systematic R&D and deal news. Daily.